<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774718</url>
  </required_header>
  <id_info>
    <org_study_id>GO42286</org_study_id>
    <secondary_id>2020-004239-25</secondary_id>
    <nct_id>NCT04774718</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors</brief_title>
  <official_title>A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children&#xD;
      and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has&#xD;
      proven to be ineffective or for whom there is no satisfactory standard treatment available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2031</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2027</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Participants with Dose-Limited Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (cycle length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Alectinib</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Alectinib Metabolite (M4)</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed Objective Response Rate (ORR): Defined as the Proportion of Participants with Complete Response (CR) or Partial Response (PR) on two Consecutive Occasions &gt;/= 4 Weeks Apart, as Determined by Blinded Independent Central Review (BICR)</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed ORR as Determined by the Investigator</measure>
    <time_frame>Up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Determined by BICR and the Investigator</measure>
    <time_frame>From the first occurrence of a documented objective response (CR or PR) to disease progression or death from any cause, whichever occurs first (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) as Determined by BICR and the Investigator</measure>
    <time_frame>From the first dose of alectinib to the first documentation of objective response (CR or PR) (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) as Determined by BICR and the Investigator</measure>
    <time_frame>6 months after the first dose of alectinib</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as Determined by BICR and the Investigator</measure>
    <time_frame>From the first dose of alectinib to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the first dose of alectinib to the date of death due to any cause (up to 10 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>ALK Fusion-positive Solid or CNS Tumors</condition>
  <arm_group>
    <arm_group_label>ALK-Fusion Positive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 is a dose-confirmation phase to confirm the recommended phase 2 dose (RP2D). In Parts 2 and 3, participants will receive alectinib at the RP2D on Days 1-28 of each 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle</description>
    <arm_group_label>ALK-Fusion Positive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histologically confirmed diagnosis of CNS or solid tumors harboring ALK gene fusions&#xD;
             as determined locally by an appropriately validated assay performed in a&#xD;
             CLIA-certified or equivalently-accredited diagnostic laboratory, or centrally by a&#xD;
             Foundation Medicine Clinical Trial Assay (CTA) or the alternative, approved central&#xD;
             laboratory for that region&#xD;
&#xD;
          -  Disease status: prior treatment proven to be ineffective (i.e. relapsed or&#xD;
             refractory), or for whom there is no satisfactory standard treatment available.&#xD;
             Disease should be measurable and evaluable as defined by Response Evaluation Criteria&#xD;
             in Solid Tumors (RECIST) v 1.1, or Response Assessment in Neuro-oncology criteria&#xD;
             (RANO) +/- bone marrow criteria for primary CNS tumors or International Neuroblastoma&#xD;
             Response Criteria (INRC)&#xD;
&#xD;
          -  Available tumor tissue for submission to the Sponsor from active disease, obtained&#xD;
             subsequent to last anti-cancer therapy regiment administered and obtained prior to&#xD;
             study enrollment, or willingness to undergo a core or excisional biopsy sample&#xD;
             collection prior to enrollment&#xD;
&#xD;
          -  For participants &lt; 16 years old, Lansky Performance Status &gt;/= 50%&#xD;
&#xD;
          -  For participants &gt;/= 16 years old, Karnofsky Performance Status &gt;/= 50%&#xD;
&#xD;
          -  Adequate bone marrow function as defined by the protocol within at least 28 days prior&#xD;
             to initiation of study drug&#xD;
&#xD;
          -  Participant and/or caregiver willingness and ability to complete clinical outcome&#xD;
             assessments throughout the study using either electronic, paper, or interviewer&#xD;
             methods&#xD;
&#xD;
          -  For females of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraception, and agreement to refrain from donating&#xD;
             eggs, as defined by the protocol&#xD;
&#xD;
          -  For males who are not surgically sterile: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraception, and agreement to refrain from donating&#xD;
             sperm, as defined by the protocol&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Medical history of: prior use of ALK inhibitors; any gastrointestinal disorder that&#xD;
             may affect absorption of oral medications, such as mal-absorption syndrome or status&#xD;
             post-major bowel resection; history of organ transplant; stem cell infusions as&#xD;
             defined by the protocol&#xD;
&#xD;
          -  Substance abuse within 12 months prior to screening&#xD;
&#xD;
          -  Familial or personal history of congenital bone disorders, bone metabolism&#xD;
             alterations, or osteopenia&#xD;
&#xD;
          -  Treatment with investigational therapy 28 days prior to initiation of study drug&#xD;
&#xD;
          -  Liver or kidney disease as defined by the protocol&#xD;
&#xD;
          -  National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)&#xD;
             v5.0 grade &gt;/=3 toxicities attributed to any prior therapy such as radiotherapy&#xD;
             (excluding alopecia), which have not shown improvement and are strictly considered to&#xD;
             interfere with alectinib&#xD;
&#xD;
          -  Co-administration of anti-cancer therapies other than those administered in this study&#xD;
&#xD;
          -  Active hepatitis B or C virus (HBV, HBC), or known HIV-positivity or AIDS-related&#xD;
             illness&#xD;
&#xD;
          -  Any clinically significant concomitant disease or condition that could interfere with,&#xD;
             or for which the treatment might interfere with, the conduct of the study or the&#xD;
             absorption of oral medications or that would, in the opinion of the Principal&#xD;
             Investigator, pose an unacceptable risk to the participant in this study&#xD;
&#xD;
          -  Any psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol requirements and/or follow-up procedures;&#xD;
             such conditions should be discussed with the participant before trial entry&#xD;
&#xD;
          -  Planned procedure or surgery during the study except as permitted treatment as defined&#xD;
             by the protocol&#xD;
&#xD;
          -  Infection considered by the investigator to be clinically uncontrolled or of&#xD;
             unacceptable risk to the participant upon induction of neutropenia, including&#xD;
             participants who are, or should be, on antimicrobial agents for the treatment as&#xD;
             active infection&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             3 months after the final dose of alectinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-LaRoche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO42286 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ny Medicin til Børn med Kræft</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone, Oncologie Pédiatrique</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris; Service d Oncologie Pediatrique</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

